Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyridoxal-dependent decarboxylase domain-containing protein 1 (PDXDC1) is a protein encoded by the PDXDC1 gene in humans and is presumed to have carboxy-lyase (decarboxylase) activity based on its homology and the presence of a pyridoxal phosphate binding domain, but its precise enzymatic function has not been clearly established in the literature[1][2][4][7]. It is a member of the family of proteins containing a pyridoxal-dependent decarboxylase domain and is predicted to be involved in amino acid and carboxylic acid metabolism. Expression is observed in multiple tissues, with the protein localized to the Golgi apparatus[2][4]. Mutations in this gene are associated with certain forms of autosomal recessive and dominant nonsyndromic deafness[2]. Currently, PDXDC1 does not appear to be a well-characterized therapeutic target, and there is no evidence for direct interaction with approved drugs or its use as a biomarker for patient selection or efficacy monitoring[2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyridoxal-dependent decarboxylase domain-containing protein 1 (PDXDC1).